Company profile: BioFire Diagnostics
1.1 - Company Overview
Company description
- Provider of multiplex PCR-based clinical diagnostics, offering the BIOFIRE and BIOFIRE FILMARRAY systems for rapid, comprehensive syndromic infectious disease testing, FDA-cleared FILMARRAY Panels for viruses, bacteria, and antimicrobial resistance genes, the high-throughput FILMARRAY TORCH, and SPOTFIRE point-of-care respiratory/sore throat solutions delivering results in about an hour or about 15 minutes.
Products and services
- BIOFIRE FILMARRAY Panels: FDA-cleared panels that test for a wide range of pathogens—including viruses, bacteria, and antimicrobial resistance genes—for comprehensive syndromic infectious disease testing
- BIOFIRE FILMARRAY System: Multiplex PCR-based diagnostic system that delivers rapid, comprehensive results for syndromic infectious disease testing
- BIOFIRE FILMARRAY TORCH: High-throughput system using multiplex PCR technology that offers rapid testing of various infectious disease targets
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioFire Diagnostics
Genetic Analysis
HQ: Norway
Website
- Description: Provider of DNA-based molecular diagnostics for gut microbiota-related diseases, leveraging GA-map array technology to rapidly profile patient gut microbiota and link to health conditions. Offers GA-map Dysbiosis Test Lx for IBS and IBD, GA-map COVID-19 fecal PCR test, clinical research services for microbiota analysis, and companion diagnostics co-development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genetic Analysis company profile →
Repare Therapeutics
HQ: Canada
Website
- Description: Provider of oncology drug discovery and development targeting synthetic lethality, leveraging the SNIPRx CRISPR-based platform to identify gene pairs and develop targeted cancer therapies. Pipeline includes camonsertib (ATR inhibitor), lunresertib (PKMYT1 inhibitor), and preclinical RP-1664 (PLK4) and RP-3467 (Polθ), with ongoing clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Repare Therapeutics company profile →
ActX
HQ: United States
Website
- Description: Provider of genomic screening and pharmacogenomic services that help physicians personalize prescriptions, identify hereditary risks, understand carrier status, and adjust dosing based on drug-genome interactions. Offers GenoACT clinical decision support integrating genetic data into EHRs with real-time alerts, plus medical genetic interpretation of 23andMe raw data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ActX company profile →
Denali Therapeutics
HQ: United States
Website
- Description: Provider of investigational therapeutics focused on neurodegenerative diseases, including BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease, DNL343 for ALS, SAR443820/DNL788 (RIPK1-targeting) for multiple sclerosis, and TAK-594/DNL593 (PTV:PGRN) for frontotemporal dementia–granulin, as well as DNL310 (ETV:IDS) for Hunter syndrome and DNL126 (ETV:SGSH) for MPS IIIA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Denali Therapeutics company profile →
Veritas Intercontinental
HQ: Spain
Website
- Description: Provider of whole genome sequencing and interpretation for consumers and physicians, offering myGenome for disease prevention and healthcare management, myPrenatal non-invasive prenatal testing, myNewborn screening for early childhood onset diseases, hereditary cardiovascular and cancer risk genetic testing, and whole genome and exome sequencing for complex cases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veritas Intercontinental company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioFire Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioFire Diagnostics
2.2 - Growth funds investing in similar companies to BioFire Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioFire Diagnostics
4.2 - Public trading comparable groups for BioFire Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →